Jounce Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €70.73M +204.8% -€43.92M -44.0% -62.1% +2.8 pp -€24.12M -66.4% -34.1% +2.7 pp
    €23.21M -56.8% -€78.39M +107.3% -337.7% -2.7 pp -€71.70M +200.1% -308.9% -2.6 pp
    €53.77M -57.8% -€37.82M -177.2% -70.3% -1.1 pp -€23.89M -5.0% -44.4% -0.25 pp
    €127.55M +126.8% €49.01M -307.5% 38.4% +0.80 pp -€25.14M -53.2% -19.7% +0.76 pp
    €56.24M -9.0% -€23.62M +66.5% -42.0% -0.19 pp -€53.70M -17.7% -95.5% +0.10 pp
    €61.80M +92.6% -€14.18M +20.0% -23.0% +0.14 pp -€65.24M -141.6% -105.6% -5.9 pp
    €32.09M +∞% -€11.82M -52.0% -36.8% -0.37 pp €156.91M -872.9% 489.0% +4.9 pp
    €0.00 +NaN% -€24.61M +171.3% N/A -€20.30M +65.6% N/A
    €0.00 -€9.07M N/A -€12.26M N/A

    Notifications